PDS Biotechnology Corporation (PDSB) Stock Score, Valuation & Financial Research

PDS Biotechnology Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PDSB

PDS Biotechnology Corporation does not currently have a complete Wall Street Score. The stored market price is USD 1.47. These figures are a research snapshot, not a buy or sell recommendation.

What PDS Biotechnology Corporation does

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

PDS Biotechnology is a clinical-stage immunotherapy company that generates no commercial revenue. Its business model relies on raising capital through equity offerings and debt to fund the research, development, and clinical trials of its proprietary Versamune and PDS01ADC technology platforms.

Products and services

  • The company develops targeted cancer immunotherapies, including its lead investigational candidate PDS0101 for HPV16-positive cancers and PDS01ADC, an IL-12 fused antibody drug conjugate.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business strengths to evaluate

  • Proprietary Versamune and PDS01ADC technology platforms Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PDSB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.47
Market capitalization:
82.21M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -33.67M
Free cash flow:
USD -27.75M
Cash:
USD 5.6M
Total debt:
USD 4.36M
EPS:
USD -0.64

What stands out

  • Free cash flow is USD -27.75M, negative for the stored period.
  • The balance sheet shows USD 5.6M of cash versus USD 4.36M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.23M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PDSB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PDSB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PDSB's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PDSB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PDSB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PDSB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.